AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KAUG 57 min read$BLLN

BillionToOne, Inc. (BLLN): Results of Operations and Financial Condition

BillionToOne, Inc. (BLLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance MENLO PARK, CA, August 5, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to al

Original reporting
SEC EDGAR 8-K
Published Aug 5, 2026, 8:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 8:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$BLLN
Bullish
high confidence
Mentioned
$BLLN
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BLLNBullishMed
01

Why it matters

Traders can update models using the reported Q2 revenue, margin, test volume, and free cash flow, then map the guidance range to expected delivery ramp around the scheduled commercial availability dates.

02

Market read

A company-specific earnings-and-guidance disclosure with concrete roadmap dates, giving traders a basis for near-term positioning and forward expectations.

03

What to watch

The guidance is reiterated rather than raised, so upside may be capped unless traders view the Aug 17 Unity expansion and Sep 1 Northstar Origin as near-term demand inflection points.

Relevance 7/10Novelty 8/10Timing: after-hours filing on Aug 5, 2026, with a same-day conference call

Background

This SEC 8-K (Item 2.02) reports BillionToOne’s Q2 2026 results and reiterates full-year 2026 revenue guidance, alongside product roadmap updates.

Company-level read

Ticker impact

$BLLNBullishHigh confidence
Context

BillionToOne reported Q2 2026 revenue of $109.4M, reiterated 2026 revenue guidance of $450M to $465M, and detailed upcoming product launches.

Expected impact

Likely positive bias for the next session as traders price in stronger Q2 growth, higher gross margin, and the Aug 17 and Sep 1 launch milestones.

Evidence & confidence

The filing includes specific, time-relevant datapoints: Q2 revenue up 64% YoY, gross margin 70%, operating income turning positive, free cash flow of $5.1M, and a reiterated full-year revenue range.

Market effects

Sector

Strength in cfDNA and oncology molecular diagnostics execution may reinforce investor appetite for profitable growth in next-gen diagnostics.

Regional

Limited direct regional spillover; primarily affects US-listed biotech/diagnostics sentiment.

Global

Modest global relevance, as the disclosure is company-specific and guidance-focused.

Counterpoint

What could challenge this read

Despite strong growth, operating expenses rose 59% YoY, so the sustainability of profitability could be questioned if investment intensity continues.

Key entities

  • public_company
    BillionToOne, Inc.

    NASDAQ-listed molecular diagnostics company reporting Q2 2026 results and reiterating 2026 revenue guidance.

  • product
    Unity Fetal Risk Screen

    Expanded 130-gene panel planned for commercial availability on Aug 17, 2026.

  • product
    Northstar Origin

    Add-on tissue-of-origin feature planned for commercial availability on Sep 1, 2026.

  • product
    Northstar Response

    Referenced in peer-reviewed data published in The Journal of Liquid Biopsy with Allegheny Health Network.

Read at source← All news

Related articles

AUG 6
$BLLNMedAI 8/10

BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move - BillionToOne (NASDAQ:BLLN)

BillionToOne (NASDAQ:BLLN) shares fell 28.12% in after-hours after reporting Q2 results. For the quarter ended June 30, 2026, revenue rose to $109.4M from $66.6M, net income was $8.1M ($0.15/share), and gross margin improved to 70%. The company kept 2026 revenue guidance of $450M to $465M and plans Unity Fetal Risk Screen (Aug. 17) and Northstar Origin (Sept. 1) launches.

benzinga.com3 min
MAY 27
$BLLNMedAI 8/10

Billiontoone (BLLN) – Research Analysts’ Recent Ratings Updates

BillionToOne (NASDAQ: BLLN) saw multiple analyst rating and target changes. Weiss Ratings upgraded BLLN to “sell (d+)” (from “sell (d)”) on 5/15 and reaffirmed “sell (d)” on 5/1. Guggenheim raised its target to $120 (from $100) and kept a “buy” on 5/13. JPMorgan lifted its target to $125 and maintained “overweight” on 5/7. BTIG cut its target to $130 (from $140) while keeping “buy” on 5/7.

dailypolitical.com1 min
SEP 17
$BWINMed

Michael Dell Just Made a $7.7 Billion Bet on This Insurance Stock

Michael Dell is acquiring Baldwin & Co. (BWIN) for $7.7B. Baldwin reported Q2 revenue of $492.9M (+30% YoY), adjusted net income of $68.5M, and adjusted EBITDA of $116.7M (+37%). Management guided Q3 revenue to $485M-$495M and full-year revenue to $2.01B-$2.05B. Analysts have mixed targets, with a consensus 'Moderate Buy' and average target of $33.

yahoo.com2 min
SEP 17
$AMZNMedAI 8/10

Should You Buy Amazon Stock For The Demand AWS Cannot Yet Serve?

Amazon.com (AMZN) stock is down 13% from its 52-week high, despite AWS's 36.7% YOY revenue growth in Q2 2026. AWS's backlog of committed contracts reached $496 billion, with demand outpacing capacity. AWS's operating margin improved 520 basis points YOY, excluding energy contract gains. Management attributes growth to AI workloads and efficient capacity use.

yahoo.com3 min
SEP 17
$ASMLMedAI 8/10

Weakness Is an Opportunity for Long-Term ASML Stock Investors

ASML's High-NA technology is gaining traction among chipmakers like Samsung, Intel, and TSMC, crucial for its long-term outlook. Q2 earnings beat estimates with €7.59 EPS and €9.33B revenue. ASML raised full-year 2026 sales guidance to €43B-€45B. Analysts have a consensus 'Hold' rating, with a mean price target of $2,350.75, implying 56% upside.

yahoo.com3 min
SEP 17
$LENMedAI 8/10

Lennar (LEN) Q3 2026 Earnings Call Transcript

Lennar (LEN) reported Q3 2026 net earnings of $284M, down 52% YoY, with GAAP EPS at $1.19. Revenues were $8B, driven by home sales. New orders and deliveries decreased due to affordability constraints. The company revised full-year delivery guidance to 80K-81K homes. Management cited higher interest rates and labor pressures as key challenges.

aol.com3 min